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Ablative radiation therapy for locally
advanced pancreatic cancer: techniques
and results
Marsha Reyngold1, Parag Parikh2 and Christopher H. Crane3*
Abstract
Standard doses of conventionally fractionated radiation have had minimal to no impact on the survival duration of
patients with locally advanced unresectable pancreatic cancer (LAPC). The use of low-dose stereotactic body
radiation (SBRT) in 3- to 5-fractionshas thus far produced a modest improvement in median survival with minimal
toxicity and shorter duration of treatment, but failed to produce a meaningful difference at 2 years and beyond. A
much higher biologically effective dose (BED) is likely needed to achieve tumor ablation The challenge is the delivery
of ablative doses near the very sensitive gastrointestinal tract. Advanced organ motion management, image guidance,
and adaptive planning techniques enable delivery of ablative doses of radiation (> = 100Gy BED) when more
protracted hypofractionated regimens or advanced image guidance and adaptive planning are used. This approach
has resulted in encouraging improvements in survival in several studies. This review will summarize the evolution of
the radiation technique over time from conventional to ablative and describe the practical aspects of delivering
ablative doses near the GI tract using cone beam CT image (CBCT) guidance and online adaptive MRI guidance.
Keywords: Pancreatic adenocarcinoma, Ablative radiation, Hypofractionated ablative radiation, IGRT, CBCT guided
radiation therapy, MRI guided radiation therapy
Background
Unresectable locally advanced pancreatic cancer con-
tinues to carry a grim prognosis with a median survival
of 10–16 months even in the context of the significant
improvement in chemotherapy options seen in the last
two decades [1]. At least a third of the patients die of
complications related to local progression with or with-
out any evidence of metastatic disease [2], and local pro-
gression may predominate as the cause of death for
patients surviving more than 15 months regardless of
their metastatic status [2, 3]. This, underscores the im-
portance of local control and suggests that improved
local control can translate into improved survival, at
least for a subset of patients. As a local modality, radi-
ation therapy has been extensively tested in this setting.
Lessons from conventional radiotherapy
experience
Standard radiotherapy options, commonly delivering 40 to
60 Gy in 1.8–2.0 Gy per fraction add minimal to no sur-
vival benefit for patients with locally advanced unresect-
able pancreatic cancer (LAPC) who have received
chemotherapy. These doses were based on the tolerability
of large field radiation to the stomach and duodenum in
the 2D and 3-D era, and have been shown to provide a
modest local tumor control benefit only. Five phase III
randomized trials evaluated the role of standard doses of
radiation delivered with concurrent chemotherapy to
chemotherapy alone in the treatment of locally advanced
pancreatic cancer with mixed results [4–8]. Inconsistent
results were seen ven when considering the three trials
performed in the 2000s in patients receiving (neo)adjuvant
gemcitabine (Table 1) [5, 7, 8]. The Fédération Franco-
phone de Cancérologie Digestive and Société Française de
Radiothérapie Oncologique (FFCD-SFRO) randomized
119 patients to chemoradiation with 60Gy in 2Gy per frac-
tion with weekly 5FU and cisplatin on weeks 1 and 5 vs
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gemcitabine alone. A large field was treated to 60Gy with-
out a cone-down. This was combined with previously
untested in the concurrent setting dose-intensified chemo-
therapy. Not surprisingly, only 42% of patients were able to
receive 75% or more of the planned concurrent radiation
and chemotherapy dose compared to 73% in the chemo-
therapy alone group. Both groups continued to receive
gemcitabine thereafter until toxicity or progression. Me-
dian OS was better in the gemcitabine alone arm (13 vs.
8.6 months, p = 0.03) undermining the role for RT in the
management of LAPC in the era of gemcitabine. It should
be noted that the particularly intensive CRT regimen that
resulted in poor compliance made the interpretation diffi-
cult. The other recent trial to compare chemoradiation to
chemotherapy alone was conducted by the Eastern
Cooperative Oncology Group (ECOG 4201). This trial
compared gemcitabine-based chemoradiation to a total
dose of 50.4Gy in 28 fractions followed by weekly gemcita-
bine to gemcitabine alone. Fields were reduced after 39.6
Gy. It randomized 74 patients before being stopped for
poor accrual. A modest median survival benefit was seen
in the chemoradiation arm (11.1 vs 9.2 months) [8].
Greater grade 4 toxicity was noted in the RT arm, although
the combined rates of grade 3–4 toxicity was similar.
The study with the greatest impact on clinical practice is
the LAP 07 trial [7]. After receiving gemcitabine +/− erloti-
nib for 4 months, 269 patient were randomized to 54Gy in
1.8 Gy per fraction with concurrent capecitabine or to 2
more months of gemcitabine. In, contrast to the trials
mentioned above, the fields were limited to gross disease
with a margin, without additional prophylactic lymph node
coverage. The median overall survival was not improved
by addition of chemoradiotherapy (16.5 vs 15.2 months, p
= 0.083). However, the use of chemoradiotherapy was asso-
ciated with reduced rates of local disease progression (32%
vs 46%, p = 0.03), longer interval to re-initiation of therapy
(6.1 vs 3.7 months, p = 0.02) and a trend toward improved
progression-free survival (HR = 0.78, p = 0.06). This was
achieved with acceptable incremental toxicity, mainly nau-
sea. Collectively these results show that conventionally
fractionated chemoradiation up to 60Gy can produce a
modest local control benefit, but only minimal, if any,
effect on survival. The reason why a local control benefit is
not translating into a survival benefit is likely multifactorial,
and likely largely influenced by the high metastatic rate
seen in this disease. However, another possibility is that for
at least the subgroup of patients with predominantly locor-
egional disease progression, gains in local control have not
been significant enough to make a difference in survival.
This underscores the need for further dose escalation.
Lack of a substantial benefit, coupled with the intro-
duction of more active systemic regimens such as FOL-
FIRINOX [9] (5-fluoruracil, oxaliplatin, leucovorin,
irinotecan) and gemcitabine and nab-paclitaxel [10],
have led to a shift at most academic centers to the much
more selective use of consolidative standard dose che-
moradiation, preferring more convenient low dose
stereotactic body radiotherapy (SBRT).
Lessons from 1- to 5-fraction stereotactic body
radiotherapy experience
Stereotactic body radiotherapy (SBRT) enables highly pre-
cise delivery of high doses of radiation to small tumor vol-
umes by using image guidance. Increased precision
coupled with evidence that a higher dose per fraction is as-
sociated with better local control has led to the emergence
of 1- to 5-fraction regimens. Evidence across several tumor
types suggests that doses of at least 100Gy BED need to be
delivered for an ablative effect or > 90% durable local con-
trol. SBRT has gained wide acceptance for targets with little
motion uncertainty such as spine or brain tumors. It is also
an attractive option for tumors occurring in moving organs
with parallel functional subunits, such as the lung or liver
whereablation of a small volume of the surrounding normal
liver or lung tissue carries no significant clinical conse-
quence. In contrast, ablative doses delivered near an organ
with serial functional subunits such as the gastrointestinal
tract, are not possible without a risk of affecting organ
function. This is particularly relevant for sites where organ
motion creates a greater degree of uncertainty about the lo-
cation of the target and sensitive structures at any given
time. For pancreatic tumors, dose delivery is limited by the
proximity of radiosensitive GI organs, primarily the duode-
num, the jejunum and the stomach, and the uncertainty
Table 1 Modern randomized trials of conventionally fractionated radiotherapy
Study N Treatment Arms mOS (months) 2y OS
FFCD-SFRO [5] 119 60Gy/30 fractions + 5Fu + cis- > gem 8.6 ~ 15%a
gem 13, p = 0.03 ~ 21%a
ECOG 4201 [8] 74 50.4Gy/28 fractions - > gem 11.1 12%
gem 9.2, p = 0.017 5%
LAP-07 [7] 269b gem+/−erlotinib -> 54Gy + cape 15.2 ~ 25%a
gem 16.5, NS
aEstimated from Kaplan-Meier curves
bResults from the second randomization are shown (patients who did not progress on induction chemotherapy)
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created by respiratory motion and day-to-day differences in
luminal organ shape.
Not surprisingly, early studies using ablative or near-
ablative doses in 1–3 fractions were associated with sig-
nificant early and/or late GI side effects (Table 2). A phase
II study evaluated single fraction SBRT of 25Gy (BED
87.5Gy for alpha/beta = 10) in 16 patients treated with
gemcitabine for 1 cycle before and until progression there-
after [11]. The dose was prescribed to the planning treat-
ment volume (PTV) with central maximal doses ranging
from 32 to 40Gy (BED 134.4 to 200Gy). Treatments were
delivered with Cyberknife using Synchrony for tracking
throughout the respiratory cycle. One-year freedom from
local progression (FFLP) was 100%, but at the expense of
late GI toxicity. Seven of 15 patients surviving > 4 months
after SBRT (47%) developed grade 2–4 gastric or duodenal
complications, including 2 patients (13%) with grade 3–4
events, all occurring 4–10 months after SBRT.
Another early report of SBRT used 45 Gy in 3 fractions
(BED 112.5Gy for alpha/beta = 10) in 22 patients [12].
Here the dose was prescribed to the center, with PTV cov-
ered by the 67% isodose line receiving 10Gy × 3. Respira-
tory motion was managed with abdominal compression.RT
was delivered using a standard linear accelerator (LINAC)
with bony anatomy used for alignment verification. PTV
size was significantly larger than in the single fraction
study, although tumor sizes in the two studies were similar.
The difference in PTV size was likely at least in part due to
the residual motion associated with abdominal compres-
sion for motion management. Local control was 57% at 6
months.Both acute and late toxicity was high at 79 and
94% respectively, with 5 of 22 patients with severe gastric
or duodenal mucositis or ulceration, including one non-
fatal perforation.
Although, comparison of hypofractionated regimens
using the linear quadratic model may be somewhat inaccur-
ate, collectively these early experiences showed that dose
escalation using very hypofractionated regimens (1–3 frac-
tions) is associated with excess toxicity, which in this setting
may be further exacerbated by any set-up uncertainties in-
cluding residual respiratory motion or using large GTV to
PTV expansions to account for such uncertainties.
To ensure safety, clinicians have adopted fractionation
schemes of 25–33 Gy in 3 to 5 fractions, which amounts
to only 54.78Gy BED using the standard linear-quadratic
conversion. A prospective multi-institutional study using
33 Gy in 5 fractions in 49 patients receiving gemcitabine
before (up to 3 weeks) and after SBRT, resulted in only
minimal acute and late GI toxicity, 2 and 10%, respect-
ively. Unfortunately, 1 year FFLP was only 78% with a me-
dian OS of 13.9 months, which is not significantly
different from results seen with conventionally fraction-
ated chemoradiation [13]. Our recent retrospective single
institution analysis showed similar outcomes with 33Gy in
5 fractions compared to conventional treatments of 50.4-
56Gy in 1.8–2.0Gy per fraction [14]. However, a study
using the National Cancer Center Database, which in-
cluded 8450 patients with LAPC showed a modest im-
provement in OS of 13.9 vs 11.6 months with SBRT,
which translated to a more modest absolute benefit at 2
years (21.7% vs 16.5%, p = 0.0014), reaching statistical sig-
nificance due to the large numbers [15]. With the advan-
tage of patient convenience, 5-fraction low dose SBRT is a
reasonable community standard. However, it falls short of
the goal of durable local tumor control which could trans-
late into a meaningful survival benefit.
Ablative hypofractionation: moving toward a new
standard
Any hope of improving outcomes in LAPC requiresdose
escalation beyond 33Gy in 5 fractions. However, safe de-
livery of higher dose per fraction as a part of a 5-fraction
regimen while respecting normal tissue constraints is
only possible for a select few patients with tumors far
away from the luminal GI tract. Relying on first princi-
ples of radiobiology, one way to achieve a higher effect-
ive total dose while maintaining an acceptable risk of
toxicity is by increasing the number of fractions. There-
fore, incorporating the precision of the SBRT technique
into a more protracted course is one way to continue
dose intensification in LAPC. Fractionation also has the
added benefit of “randomizing” the internal day-to-day
organ motion, making it less likely that unintended high
dose will be delivered to a normal structure that may
move closer to the target on any given day.
Another conceptual change that would facilitate dose
escalation is abandoning the goal of dose homogeneity
with the tumor planning treatment volume (PTV). Dose
homogeneity as a planning goal is largely a carry-over
from more conventional planning approaches. When-
large treatment fields contained the target as well as the
organs at risk, hotspots within the irradiatedvolume
Table 2 Representative SBRT studies
Study N RT Dose mOS (months) GI toxicity (Gr ≥ 2)
Schellenberg et al. [11] 16 25Gy × 1 11.4 Acute 19%
Late 47%
Hoyer et al. [12] 22 15Gy × 3 5.7 Acute 79%
Herman et al. [13] 49 6.6Gy × 5 13.9 Acute 2%
Late 11%
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were undesirable. However, when the planning treat-
ment volume is small and limited to the tumor, exclud-
ing all sensitive normal structures, a hotspot within that
treatment volume has no detrimental effect. On the con-
trary, allowing a hotspot may improve the conformality
of the high dose distribution thereby enabling dose es-
calation. Importantly, the center of a tumor is typically
more hypoxic than the periphery and, therefore, more
radioresistant. A hotspot within a more radioresistant
portion of the tumor will only be of benefit. Thus our
novel treatment planning strategy represents a three-
part approach of (1) covering as much of the tumor as
possible with an ablative dose while (2) placing supra-
ablative hotspots in the center and (3) restricting the
areas directly abutting the GI tract to safe doses used in
conventional radiotherapy (Fig. 1).
The original series combining these concepts with the
stereotactic techniques prescribed 63–70 Gy in 28 frac-
tions or 67.5 Gy in 15 fractions; BED, 77.2–97.9 Gy.
Moderate inspiration breath hold respiratory gating with
daily breath hold CT-on-Rails fiducial free 3D image
registration were used for motion management and
image guidance. Unprecedented 3-year OS of 35% and
5-year OS of 18% far exceed historical controls with <
5% in unresected patients surviving past 5 years [16].
These results compare favorably to surgical resection in
patients with less advanced local disease and constitute a
proof of principle that definitive radiation doses can re-
sult in a meaningful long-term survival. An ongoing
phase II clinical trial (NCT03523312) is evaluating these
doses in a prospective manner.
Daily adaptive planning using novel MR linear acceler-
ators is another way to overcome the limitations posed
by the motion of the GI tract. This technology allows
visualization of the tumor and critical GI structures, as
well as the ability to create a plan of the day that maxi-
mizes dose to the pancreas and conforms it to the GI or-
gans at risk on a fraction-by-fraction basis [17] This
a b
c d
Fig. 1 Contouring and plan evaluation. a and c Simulation CTs showing GTV (cyan), PTV high dose (red) and PTV microscopic dose (yellow) as
well as stomach (orange) with a carve-out structure (brown) used to ensure exclusion of stomach from PTV high dose as demonstrated by the
white arrow. b and d Dose distributions with the lowest displayed dose set to the critical max point dose for stomach (60Gy). White arrow
indicates that 60Gy isodose line is away from the surface of the stomach, which was achieved by creating a PRV (not shown). c and d An
example that includes an optional PTV ultra-high dose (magenta)
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technique, Stereotactic MR-guided Adaptive Radiation
Therapy [18] was utilized to deliver ablative doses of radi-
ation (67.5 Gy / 15 fractions; 50 Gy / 5 fractions) based on
the original promising results from MD Anderson listed
above [16]. When these were compared with patients re-
ceiving non-ablative doses of MRI-guided radiation, there
was a significant survival advantage with overall survival
from diagnosis of 71% at 2 years in the SMART patients
and 25% in the standard dose patients [19]. Moreover, the
SMART patients had no grade 3 or higher toxicity, whilst
3 patients in the standard, non-adaptive group had grade
3 or higher toxicity. A prospective, phase II multi-
institutional study (NCT03621644) investigating 50 Gy in
5 fractions with SMART is open, and we will await these
results to see if they show similar effectiveness.
This technology provides a useful platform to dose es-
calate pancreatic tumors without increased fractionation.
The challenges from a population-based perspective are
the limited availability of the technology, and labor in-
tensiveness of the workflow requiring physician/physicist
time at each fraction. For patients and institutions that
do not have access to this technology, optimized cone
beam image-guidance delivered in 15 to 25 fractions
with adaptive planning on as-needed basis is a more
workflow-friendly approach.
Practical considerations
Ablative hypofractionation technique using cone beam
image-guidance
Our current approach is to use IMRT with a simultan-
eously integrated boost (SIB) dose painting, typically
with 2 or 3 different planning target volumes (PTVs) (a
microscopic dose, a SIB to the GTV, and if possible, a
second SIB to a higher dose to the hypoxic center). We
predominantly use 15 or 25-fraction schedules based on
the proximity to the luminal GI tract. For tumors lo-
cated within 1 cm of the GI tract, we use a 25-fraction
regimen, for tumors more than 1 cm away we use a 15-
fraction regimen, with a 5-fraction regimen reserved for
very select patients with no nearby GI structures. Typ-
ical regimens are listed in Table 3. The bowel dose con-
straints are based on a previous analysis and listed in
Table 3 [20]. With these constraints, no grade 4 or
greater bleeding events have occurred to date.
Simulation
We simulate patients in the supine position with cus-
tomized immobilization and arms elevated. Using the
Varian RPM system, we obtain deep inspiration breath
hold (DIBH) scans with diagnostic CT pancreatic proto-
col (150 mL iodinated contrast at 5 mL/s) with imaging
at 45 s after the start of contrast administration and a
second image obtained at between 1 min 30 s and 2 min
after the start of the contrast bolus. This technique al-
lows maximal contrast enhancement of the surrounding
parenchyma around the tumor as well as arterial and
portal venous enhancement on the first scan, which is
usually used as the planning CT scan.
Contouring
The most critical aspect of contouring is to exclude all
organs at risk (OARs) with an additional safety margin
from the high and ultra-high dose PTVs (Fig. 1, Table 3).
For this we contour three GI organs at risk that have
distinct constraints during the planning process, (1)
stomach with the first two segments of the duodenum,
(2) the rest of small bowel and (3) large bowel. A margin
of 3 to 5 mm is added to create the corresponding plan-
ning OAR volumes (PRVs) to be used as avoidance
structures during planning. To create PTV high dose, a
margin of 0-5 mm is added to the gross tumor volume
(GTV) of the primary tumor, then all organs at risk
(OARs) with an additional safety margin of 5 to 7 mm
are excluded. The exact margin depends on the length
of the interface of the tumor with the OAR, with greater
margins utilized for cases with more extensive abutment.
Table 3 Ablative radiotherapy prescription definitions and normal tissue constraints
Planning Volumes Definition Doses by Fractionation Scheme
15-Fraction 25-Fraction
Prescriptions Microscopic Extension PTV CTV + 5 mm
CTV = GTV + 1 cm + CA, SMA,
+/− porta hepatis, +/− splenic
hilum basins
37.5Gy/15 45Gy/25
High Dose PTV GTV + 0-5 mm margin excluding
GI OAR + 5–7 margin
67.5Gy/15 75Gy/25
Ultra High Dose PTVa 1 cm contraction of High Dose PTV 90Gy/15 100Gy/25
Constraints Stomach-Duodenum PRV Stomach and duodenum segments
1 and 2 + 3-5 mm
Dmax <45Gy Dmax <60Gy
Small Bowel PRV All other small bowel + 3-5 mm Dmax <40Gy Dmax <55Gy
Large Bowel PRV Large bowel + 3-5 mm Dmax <50Gy Dmax <65Gy
aPossible in select patients only
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In this process, the edge of the PTV high dose will be sepa-
rated from the PRVs by at least 2 mm, effectively prevent-
ing the high dose gradient from falling immediately
adjacent to the sensitive organ where small amount of
uncertainty can place the organ at risk within a very high
dose region (Fig. 1b, d). To create a PTVmicroscopic dose, we
first create a CTV by expanding the GTV of the primary
tumor and involved nodes by 1 cm and including the
celiac axis and superior mesenteric artery nodal basins in
the CTV. and then adding a 5 mm set-up uncertainty
margin. In the appropriate clinical context, porta hepatis
and splenic hilum nodal basins may also be included. In
select cases, where the tumor is large enough and the
GTV does not involve bile ducts or the aorta, a PTVvery
high dose is created by doing a contraction of the PTVhigh
dose by 1 cm.
The dual purpose of DIBH
Management of both respiratory and day-to-day internal
organ motion is paramount. At MSK we currently use
DIBH respiratory gating using RPM Varian system with
daily DIBH cone-beam CT (CBCT) image registration. The
presence of fiducial markers or a metal biliary stent are
required. DIBH is the solution for intra-fraction motion,
and enables acquisition of high quality daily CBCT scans
by eliminating motion artifact. CBCTs are used to verify
the target position as well as day-to-day variation in the
position of the adjacent luminal GI tract. The latter is used
to select cases for adaptive planning as described below.
It should be noted that despite using DIBH, some
CBCTs will provide poor visualization of the luminal GI
tract due to other sources of artifact such as luminal gas
and peristalsis. However, the additional advantage of a
multifraction regimen is that a small number of fractions
where the doses to the GI tract are uncertain do not
alter the risk profile of the overall treatment plan. Thus,
such scans will not necessarily cause treatment delays as
long as the position of the target can be verified. The
process of using CBCTs to evaluate GI organ position is
described in the subsequent section.
Other methods of motion management and image
guidance may be used depending on the availability of
technology and proficiency of a particular center. These
include gating, tumor tracking or abdominal compres-
sion for respiratory motion management. In addition to
CBCTs, CT-on-Rails or MRI may be used for image
guidance.. For all methods of image guidance, motion
management will reduce artifact.
Selective adaptive planning
Adaptive planning is used as a solution for non-random
motion of the GI tract. We evaluate day-to-day organ
motion using daily CBCT by projecting maximum point
dose isodose line (Table 3) as a structure on our daily
CBCTs (Fig. 2). The position of the stomach, duodenum,
jejunum and colon with respect to the projected IDLs is
easily noted. Adaptive planning is triggered when the
same part of an organ crosses that isodose line more
than one third of the time. Such selective adaptive plan-
ninghas been borne out of experience of the past 10
years. This approach minimizes the number of adaptive
plans, and increases operational efficiency. The most
common reasons for adaptive planning are related to gas
in the stomach, non-random jejunal motion, and gas in
the duodenal bulb. When an adaptive plan is necessary,
a CBCT fused to the simulation CT can be used to re-
contour the OARs on the simulation CT and re-plan
without repeating the simulation.
Concurrent chemotherapy
Most patients treated with ablative hypofractionated
technique to date have received concurrent radiosensi-
tizing chemotherapy. Current MSKCC standard is oral
capecitabine twice daily on the days of radiation. Main
toxicities include nausea, fatigue, diarrhea, and hand-
foot symptoms. The exact contribution of radiosensitiza-
tion to ablative radiotherapy is not known, but there are
possible advantages to both locoregional and systemic
disease control.
Current techniques with stereotactic MR guided adaptive
radiation therapy
Important aspects of simulation
Patients are simulated with a guided breath hold, supine,
with one arm up or both arms down to ensure comfort
during the treatment. IV contrast is used similarly as
above.
Contouring / GI OARs
The most critical aspect of contouring is to identify the
stomach, duodenum, small and large bowel within 3 cm
of the CTV. The CTV includes the gross tumor, con-
toured generously to include the superior mesenteric ar-
tery and celiac artery when feasible. The CTV is
expanded by 3 mm to create a PTV.
The role of MRI motion management
Motion management and accuracy of treatment delivery
are important in these high dose treatments. The MRI-
linear accelerator used automatically processes 4 cine
images per second, allowing the patient to be treated
with guided breath holds or with gating on free breath-
ing, based on patient comfort.
Daily adaptive planning
Daily adaptive planning is the hallmark of this technique.
On each fraction, the patient undergoes a couch shift to
align the CTV based on simulation. At this time, the GI
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OARs are re-contoured within 3 mm of the PTV. A new
plan is generated whenever the volume of each GI OAR
exceeds 1 cc above 33 Gy for a 5-fraction treatment.
Each fraction is evaluated separately, since technology
does not yet exist to deformably map dose between dif-
ferent bowel loops.
Conclusions
Treatment paradigms for locally advanced pancreas
adenocarcinoma have evolved significantly over the last
several years, primarily due to the expanded chemother-
apy options. Likewise, there have been significant im-
provements in radiation therapy delivery techniques
with the advent of SBRT.However the potential offered
by these techniques has not been fully harnessed with
the commonly used 1–5 fraction SBRT regimens. These
technological advances enable delivery of radiotherapy
doses that are at least 1.5 as potent as conventionally
fractionated schedules or the commonly used low dose
1–5 fraction SBRT regimens, and are predicted to be ab-
lative. Multiple single institution series show promising
early results, and there are ongoing phase II studies
investigating ablative radiation using a CBCT- and an
MR-based approaches.
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